Caris Life Sciences, Inc.
Caris Life Sciences Inc. (NASDAQ: CRIS) is a patient-centric artificial intelligence and precision medicine company that develops and commercializes molecular profiling solutions primarily focused on oncology. The company operates through its comprehensive Caris platform, which combines next-generation sequencing,… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Caris Life Sciences, Inc. does
In the company’s own words
Caris Life Sciences Inc. (NASDAQ: CRIS) is a patient-centric artificial intelligence and precision medicine company that develops and commercializes molecular profiling solutions primarily focused on oncology. The company operates through its comprehensive Caris platform, which combines next-generation sequencing, artificial intelligence, and machine learning technologies to generate detailed molecular information about patients' tumors and guide personalized treatment decisions.
The company's core business centers on its Molecular Intelligence product portfolio, which includes three primary platforms. MI Profile represents its tissue-based whole exome and whole transcriptome sequencing solution for cancer therapy selection, with approximately 170,300 clinical cases processed in 2025. Caris Assure is its blood-based profiling solution offering similar comprehensive sequencing capabilities with the unique ability to subtract clonal hematopoiesis mutations to distinguish tumor-derived variants from age-related blood mutations. The Precision Whole Genome Platform encompasses several solutions under development, including Caris Detect, a multi-cancer early detection assay expected to launch in 2026, along with Caris WGS MRD for minimal residual disease tracking and Caris ChromoSeq for hematological cancers.
Beyond clinical diagnostics, Caris operates Caris Discovery, a drug discovery and development business that leverages its proprietary datasets and platforms to identify novel drug targets and develop therapeutics in partnership with biopharma companies. The company has established the Caris Precision Oncology Alliance, a network of leading cancer centers and research institutions collaborating on precision oncology research and biomarker development.
As of December 31, 2025, Caris has performed sequencing on over one million cases, creating what it believes to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology. The company serves over 6,000 ordering physicians across major health systems, academic cancer institutions, and community settings throughout the United States. Its biopharma partnerships include collaborations with companies such as Moderna, AbbVie, Xencor, Merck KGaA, and Genentech. The company was founded in 2008 and operates as a smaller reporting company on the NASDAQ exchange. More information is available at www.carislifesciences.com.
Company details
- Sector
- Healthcare
- Industry
- Health Services
- Headquarters
- IRVING, TX
- Fiscal year end
- December
- CIK
- 2019410
- SIC
- 8071
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Caris Life Sciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Caris Life Sciences, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Caris Life Sciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Caris Life Sciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Caris Life Sciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Caris Life Sciences, Inc.'s last four quarterly filings that the numbers alone won't show?”